Biopharmaceutical company Korro Bio, Inc. (KRRO) announced Monday a collaboration with Danish healthcare company Novo Nordisk A/S (NVO) to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases.
The collaboration brings together Novo Nordisk's deep cardiometabolic disease understanding and drug development experience with Korro's proprietary platform to develop RNA editing product candidates for two undisclosed targets.
Under the terms of the agreement, Korro is eligible to receive up to $530 million in upfront, development and commercial milestone payments, in addition to tiered royalties and R&D funding.
Korro will advance up to two programs through preclinical development after which point Novo Nordisk could further advance the programs through clinical studies.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.